These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 19690858)
1. Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate. Sawaki A; Yamada Y; Komatsu Y; Kanda T; Doi T; Koseki M; Baba H; Sun YN; Murakami K; Nishida T Cancer Chemother Pharmacol; 2010 Apr; 65(5):961-7. PubMed ID: 19690858 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Benjamin RS; Schöffski P; Hartmann JT; Van Oosterom A; Bui BN; Duyster J; Schuetze S; Blay JY; Reichardt P; Rosen LS; Skubitz K; McCoy S; Sun YN; Stepan DE; Baker L Cancer Chemother Pharmacol; 2011 Jul; 68(1):69-77. PubMed ID: 20838998 [TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Shirao K; Nishida T; Doi T; Komatsu Y; Muro K; Li Y; Ueda E; Ohtsu A Invest New Drugs; 2010 Dec; 28(6):866-75. PubMed ID: 19730791 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). Nishida T; Shirao K; Sawaki A; Koseki M; Okamura T; Ohtsu A; Sugiyama T; Miyakawa K; Hirota S Int J Clin Oncol; 2008 Jun; 13(3):244-51. PubMed ID: 18553235 [TBL] [Abstract][Full Text] [Related]
5. Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. von Mehren M Clin Colorectal Cancer; 2006 Nov; 6 Suppl 1():S30-4. PubMed ID: 17419150 [TBL] [Abstract][Full Text] [Related]
6. Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives. Apice G; Milano A; Bruni GS; Iaffaioli RV; Caponigro F Rev Recent Clin Trials; 2006 Jan; 1(1):35-42. PubMed ID: 18393778 [TBL] [Abstract][Full Text] [Related]
7. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Joensuu H; De Braud F; Coco P; De Pas T; Putzu C; Spreafico C; Bono P; Bosselli S; Jalava T; Laurent D; Casali PG Ann Oncol; 2008 Jan; 19(1):173-7. PubMed ID: 17698976 [TBL] [Abstract][Full Text] [Related]
8. [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications]. Italiano A; Bui B Bull Cancer; 2008 Jan; 95(1):107-16. PubMed ID: 18230576 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. Schlumberger MJ; Elisei R; Bastholt L; Wirth LJ; Martins RG; Locati LD; Jarzab B; Pacini F; Daumerie C; Droz JP; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Sherman SI J Clin Oncol; 2009 Aug; 27(23):3794-801. PubMed ID: 19564535 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors. Li J; Gao J; Hong J; Shen L Future Oncol; 2012 May; 8(5):617-24. PubMed ID: 22646775 [TBL] [Abstract][Full Text] [Related]
11. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study. Rutkowski P; Bylina E; Klimczak A; Switaj T; Falkowski S; Kroc J; Lugowska I; Brzeskwiniewicz M; Melerowicz W; Osuch C; Mierzejewska E; Wasielewski K; Woźniak A; Grzesiakowska U; Nowecki ZI; Siedlecki JA; Limon J BMC Cancer; 2012 Mar; 12():107. PubMed ID: 22439647 [TBL] [Abstract][Full Text] [Related]
12. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Sawaki A; Nishida T; Doi T; Yamada Y; Komatsu Y; Kanda T; Kakeji Y; Onozawa Y; Yamasaki M; Ohtsu A Cancer; 2011 Oct; 117(20):4633-41. PubMed ID: 21456006 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Demetri GD; van Oosterom AT; Garrett CR; Blackstein ME; Shah MH; Verweij J; McArthur G; Judson IR; Heinrich MC; Morgan JA; Desai J; Fletcher CD; George S; Bello CL; Huang X; Baum CM; Casali PG Lancet; 2006 Oct; 368(9544):1329-38. PubMed ID: 17046465 [TBL] [Abstract][Full Text] [Related]
14. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. Prior JO; Montemurro M; Orcurto MV; Michielin O; Luthi F; Benhattar J; Guillou L; Elsig V; Stupp R; Delaloye AB; Leyvraz S J Clin Oncol; 2009 Jan; 27(3):439-45. PubMed ID: 19064982 [TBL] [Abstract][Full Text] [Related]
15. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Joensuu H; De Braud F; Grignagni G; De Pas T; Spitalieri G; Coco P; Spreafico C; Boselli S; Toffalorio F; Bono P; Jalava T; Kappeler C; Aglietta M; Laurent D; Casali PG Br J Cancer; 2011 May; 104(11):1686-90. PubMed ID: 21540861 [TBL] [Abstract][Full Text] [Related]
16. Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors. Fujisaka Y; Yamada Y; Yamamoto N; Shimizu T; Fujiwara Y; Yamada K; Tamura T; Watanabe H; Sun YN; Bass MB; Seki M Cancer Chemother Pharmacol; 2010 Oct; 66(5):935-43. PubMed ID: 20107802 [TBL] [Abstract][Full Text] [Related]
17. Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy. Kanda T; Ishikawa T; Hirota S; Yajima K; Kosugi S; Ohashi M; Suzuki S; Mashima Y; Ajioka Y; Hatakeyama K Jpn J Clin Oncol; 2012 Jul; 42(7):578-85. PubMed ID: 22523393 [TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. George S; Blay JY; Casali PG; Le Cesne A; Stephenson P; Deprimo SE; Harmon CS; Law CN; Morgan JA; Ray-Coquard I; Tassell V; Cohen DP; Demetri GD Eur J Cancer; 2009 Jul; 45(11):1959-68. PubMed ID: 19282169 [TBL] [Abstract][Full Text] [Related]
19. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Demetri GD; Casali PG; Blay JY; von Mehren M; Morgan JA; Bertulli R; Ray-Coquard I; Cassier P; Davey M; Borghaei H; Pink D; Debiec-Rychter M; Cheung W; Bailey SM; Veronese ML; Reichardt A; Fumagalli E; Reichardt P Clin Cancer Res; 2009 Sep; 15(18):5910-6. PubMed ID: 19723647 [TBL] [Abstract][Full Text] [Related]
20. Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer. De Boer RH; Kotasek D; White S; Koczwara B; Mainwaring P; Chan A; Melara R; Ye Y; Adewoye AH; Sikorski R; Kaufman PA Breast Cancer Res Treat; 2012 Aug; 135(1):241-52. PubMed ID: 22872523 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]